Financial burden of drugs prescribed for cancer-associated symptoms

A Gupta, L Nshuti, US Grewal, R Sedhom… - JCO Oncology …, 2022 - ascopubs.org
PURPOSE: The financial toxicity of anticancer drugs is well-documented, but little is known
about the costs of drugs used to manage cancer-associated symptoms. METHODS: We …

Finding the lowest-cost pharmacy for cancer supportive care medications: not so easy

A Etteldorf, S Rotolo, R Sedhom, RI Vogel… - JCO Oncology …, 2022 - ascopubs.org
PURPOSE: To decrease the financial burden on people with cancer, clinicians and patients
increasingly use medication price comparison websites to seek pharmacies where …

An observational post‐authorization safety study (PASS) of naloxegol drug utilization in four European countries

G Kvarstein, AMS Kindlundh‐Högberg… - … and Drug Safety, 2024 - Wiley Online Library
Purpose Naloxegol has been shown to be an efficient alternative to treat opioid‐induced
constipation (OIC). This study aimed at describing the characteristics of naloxegol users and …

Projected 30-day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D

A Gupta, N Premnath, R Sedhom, MS Beg, R Khera… - Pancreatology, 2021 - Elsevier
Methods We used Medicare Part D formulary and pricing files for the first quarter of 2020 to
describe total (patient and payer) and out-of-pocket costs for each PERT formulation among …

[引用][C] Payer-imposed quantity limits for antiemetics: everybody hurts

W Haque, R Sedhom, F Chino, TJ Royce… - JCO Oncology …, 2022 - ascopubs.org
Antiemetics represent one of the greatest advances in modern oncology; perhaps no other
intervention has improved the quality of life of people receiving anticancer therapy more …